Assay Detail
Functional
CHEMBL1959554
Review assay metadata, readout intent, target linkage, and publication context from the same page.
Cytotoxicity against human primary leukemia cells isolated from acute myeloid leukemia patient expressing FLT3-D835Y mutation assessed as cell viability after 72 hrs by luciferase assay
10
Total Activities
10
Compounds Tested
1
Activity Types
0
Assay Parameters
Assay Information
| Assay Type | Functional |
| Organism | Homo sapiens |
| Cell Type | Leukemia cell |
| Confidence | 1 — Organism |
| Curated By | Autocuration |
Publication
VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia.
Activity Statistics
| Type | Count | Avg pChEMBL | Best pChEMBL |
|---|---|---|---|
| IC50 | 10 | 5.93 | 6.66 |
Compounds Tested
| Compound | Name | Phase | Activities | Best pChEMBL |
|---|---|---|---|---|
| CHEMBL1835870 | — | — | 1 | 6.66 |
| CHEMBL1835749 | — | — | 1 | 6.62 |
| CHEMBL1835867 | — | — | 1 | 6.52 |
| CHEMBL1835747 | — | — | 1 | 6.51 |
| CHEMBL941 | IMATINIB | 4.0 | 1 | 6.30 |
| CHEMBL535 | SUNITINIB | 4.0 | 1 | 5.96 |
| CHEMBL124660 | TANDUTINIB | 2.0 | 1 | 5.47 |
| CHEMBL1833992 | — | — | 1 | 5.23 |
| CHEMBL1835746 | — | — | 1 | 5.05 |
| CHEMBL1835743 | — | — | 1 | 4.98 |
Activity Data
| Compound | Name | Type | Rel. | Value | Units | pChEMBL |
|---|---|---|---|---|---|---|
| CHEMBL1835870 | — | IC50 | = | 220.0 | nM | 6.66 |
| CHEMBL1835749 | — | IC50 | = | 240.0 | nM | 6.62 |
| CHEMBL1835867 | — | IC50 | = | 300.0 | nM | 6.52 |
| CHEMBL1835747 | — | IC50 | = | 310.0 | nM | 6.51 |
| CHEMBL941 | IMATINIB | IC50 | = | 500.0 | nM | 6.30 |
| CHEMBL535 | SUNITINIB | IC50 | = | 1100.0 | nM | 5.96 |
| CHEMBL124660 | TANDUTINIB | IC50 | = | 3400.0 | nM | 5.47 |
| CHEMBL1833992 | — | IC50 | = | 5900.0 | nM | 5.23 |
| CHEMBL1835746 | — | IC50 | = | 8900.0 | nM | 5.05 |
| CHEMBL1835743 | — | IC50 | = | 10500.0 | nM | 4.98 |